Loading
  • Twitter
  • Linkedin
  • Youtube
  • Careers
  • Contact Us
  • Sign Up for Alerts
Poseida
  • Company
    • About Us
    • Leadership
    • Board of Directors
  • Technology
    • Overview
    • PiggyBac DNA Modification
    • Cas-CLOVER Gene Editing
    • Gene Delivery
    • Additional Tools
    • Gene Engineering
  • Pipeline
    • Programs
    • CAR-T Therapies
    • New Gene Therapies
  • Patients
    • About CAR-T Therapy
    • Clinical Trials
  • Media
    • Press Releases
    • Media Contact
    • Publications
  • Menu

Media

Stay up to date on Poseida Therapeutics’ news and events.

11/05/2019/by poseida super

Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting

Press Releases

11/05/2019/by poseida super

Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting

10/10/2019/by poseida super

Poseida Therapeutics Appoints Kerry Ingalls as Chief Operating Officer

05/13/2019/by jcalhoon

Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma

04/22/2019/by poseida super

Poseida Therapeutics Raises $142 Million in Series C Financing

02/13/2019/by poseida super

Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks

01/04/2019/by poseida super

Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions

12/03/2018/by jnellis

Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting

11/29/2018/by jcalhoon

Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting

11/05/2018/by jcalhoon

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101

10/09/2018/by jcalhoon

Poseida Therapeutics Appoints Marcy Graham as Vice President, Corporate Affairs

Media Contact

Marcy Graham
Vice President, Corporate Affairs
858.779.3108
mgraham@poseida.com

CompanyAbout UsLeadershipBoard of Directors

TechnologyOverviewPiggyBac DNA ModificationCas-CLOVER Gene EditingGene DeliveryAdditional ToolsGene Engineering

PipelineProgramsCAR-T TherapiesNew Gene Therapies

PatientsAbout CAR-T TherapyClinical Trials

MediaPress ReleasesMedia ContactPublications

Copyright © 2018 Poseida Therapeutics, Inc. | All Rights Reserved | Privacy Policy | Expanded Access Policy

Scroll to top